Tumor vaccination involving a humoral immune response against self-proteins

US9617321B2 · kind B2 · utility

Assignees

• Johannes Gutenberg-Universität Mainz · DE
• BioNTech AG · DE

Inventors

• Thorsten Klamp · Mainz, DE
• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Michael Koslowski · Mainz, DE
• Thomas Hiller · Mainz, DE
• Jens Schumacher · Heidelberg, DE

Key dates

• Filing date: Aug 12, 2014
• Grant date: Apr 11, 2017
• Expiry date: Aug 12, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2730/10171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.